SCHEMBL6645289

SCHEMBL6645289

Cc1ccc(C(=O)Nc2ccc(OCCn3nccc3NC(c3ccccc3)(c3ccccc3)c3ccccc3)cc2)c(N2CCC(C)CC2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 3/20 0.37
LMNA P02545 1/20 0.37
KCNA5 P22460 1/20 0.37
BRPF1 P55201 1/20 0.37
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 2/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 2/20 0.35
AURKA O14965 1/20 0.35
MET P08581 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6645748 0.88 ALDH1A1 (0.38) MAPTTP53SMN1; SMN2ALDH1A1LMNA
SCHEMBL6645107 0.84 KCNA5 (0.39) MAPTTP53SMN1; SMN2ALDH1A1LMNA
SCHEMBL6646113 0.84 ALDH1A1 (0.40) MAPTTP53SMN1; SMN2ALDH1A1LMNA
SCHEMBL6645158 0.80 THRB (0.47) MAPTTP53SMN1; SMN2ALDH1A1LMNA
SCHEMBL6643270 0.78 ALDH1A1 (0.45) MAPTTP53SMN1; SMN2ALDH1A1ADRB2
SCHEMBL6648929 0.78 TAS1R3 (0.42) MAPTTP53SMN1; SMN2ALDH1A1KCNA5
SCHEMBL6649240 0.76 KCNA5 (0.40) TP53SMN1; SMN2KCNA5KMT2AKDM4E
SCHEMBL6645258 0.74 ALDH1A1 (0.36) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL6646979 0.73 MAPT (0.40) MAPTTP53SMN1; SMN2ALDH1A1LMNA
SCHEMBL7199389 0.73 MAPT (0.50) MAPTTP53SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR MAPT 4101/4885TP53 4513/4885SMN1; SMN2 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.